Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) Gross Margin (2016 - 2025)

Iradimed (IRMD) has disclosed Gross Margin for 13 consecutive years, with 77.8% as the latest value for Q3 2025.

  • On a quarterly basis, Gross Margin rose 36.0% to 77.8% in Q3 2025 year-over-year; TTM through Sep 2025 was 77.07%, a 6.0% decrease, with the full-year FY2024 number at 76.94%, up 43.0% from a year prior.
  • Gross Margin was 77.8% for Q3 2025 at Iradimed, roughly flat from 78.17% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 79.71% in Q2 2022 to a low of 74.74% in Q2 2021.
  • A 5-year average of 76.95% and a median of 76.86% in 2023 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: soared 497bps in 2022, then crashed -416bps in 2023.
  • Iradimed's Gross Margin stood at 77.91% in 2021, then dropped by -3bps to 75.49% in 2022, then rose by 2bps to 76.86% in 2023, then decreased by -1bps to 76.13% in 2024, then grew by 2bps to 77.8% in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Gross Margin are 77.8% (Q3 2025), 78.17% (Q2 2025), and 76.08% (Q1 2025).